Chart Check: After 30% rally from 52-week low, this pharma stock could retest Rs 3,900 levels; time to buy?

Divi’s Laboratories, a pharmaceutical company, has seen a rally of over 30% since March 2023. The stock has surpassed key moving averages and the chart pattern suggests that the rally may continue. Experts suggest that short-term traders could buy the stock, with a possible target above Rs 3,900 in the next 3-4 weeks. The stock has found support above Rs 3,000 and is trading above various moving averages. The Relative Strength Index (RSI) is at 59.6, indicating bullish momentum.